Top

News & Events

Client News

Client News

UK BIOTECH BOOM: 65% growth in UK biotechnology research and development companies since 2016 as sector attracts record investment

The number of active UK biotechnology businesses in the field of research and experimental development has soared by 65% in just over three years as the sector attracts record levels of funding, according to new analysis by investment manager Downing LLP.

Read more »

National Care Group expands in Gloucester by completing acquisition of Branksome House Care Services

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of Branksome House Care Services (“Branksome”), through its subsidiary Chosen Care Limited. Financial details of the deal were not disclosed.

Read more »

Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

Sydney, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

Read more »

ART MEDICAL: New Technologies Needed to Address Inadequate Implementation of Nutritional Guidelines Across the Majority of Intensive Care Units

Tel Aviv, Israel – ART MEDICAL, a medical device company that specializes in nutrition-based intensive care unit (ICU) technology, today announced the publication of an article that outlines the limitations of current ICU nutrition methods and provides insights into cutting-edge technologies that may advance this critical component of patient care into the 21st Century.  Pierre Singer, Professor of Anesthesia and Intensive Care, Sackler School of Medicine, Tel Aviv University, and ART MEDICAL CEO, Liron Elia, co-authored the article, which appears in the current issue of ICU Management & Practice Journal.

Read more »

China National Biotec Group (CNBG) and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China

Cambridge, UK - ImmunoBiology Ltd (ImmBio), a vaccine R&D company based at Babraham Research Campus near Cambridge UK, has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product) a subsidiary company under CNBG.

Read more »

USA Patent Granted for Recce's Antibiotics

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.

Read more »

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

Read more »

Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, nutrition and digital/connected health sectors, Health for Life Capital II™ (HFL II), with a target for the final close of over €200 million.

Read more »

Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies.

Read more »

Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.

Read more »

Seventure Partners Life Sciences Corporate Update September 2018 – February 2019

Paris, France – Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, is pleased to provide an update on its life science investments for the period September 2018 to February 2019.
 

Read more »

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, who will serve as Chairman of the SAB.

Read more »

Clinigen half year results - Good H1 performance with adjusted EPS up 9% and strong cash flow

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its half year results for the six months ended 31 December 2018.

Read more »

Dr. Athanasios Papadopoulos joins Emergex as Chief Medical Officer

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.

Read more »

Abcam moves to new purpose-built global headquarters

Cambridge, UK - Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research.

Read more »

Cell Medica Awarded USD 8.7 Million CPRIT Grant to Accelerate CMD-502 Off-the-shelf CAR-NKT Cell Therapy into Clinical Development

HOUSTON and LONDON – Cell Medica announced today that it has been awarded an $8.7 million research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support preclinical and clinical development of the company’s off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) therapies to treat hematological and solid tumors.

Read more »

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

Houston, Texas and Tuebingen, Germany – Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers.

Read more »

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has completed a $37.4 million (€33.2 million) series D financing.

Read more »

Clinigen granted additional indication for Glycopyrronium Bromide to treat paediatric and adolescent severe hypersalivation

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), an additional indication for Glycopyrronium Bromide 1mg/5ml Oral Solution (‘Glyco’). The new indication covers the use of Glyco in children and adolescents aged three years and older with chronic neurological disorders as symptomatic treatment of hypersalivation (severe sialorrhoea).

Read more »

Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, has closed four new investments across four countries over the past few months. The investments span the spectrum of venture investing, from seed to series C.

Read more »

Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection

Copenhagen, Denmark and Buffalo Grove, IL, USA - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market. This approval follows Qualified Infectious Disease Product (QIDP) designation from the FDA in February 2018.

Read more »

SkinBioTherapeutics plc - Issue of Equity and Related Party Transaction

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX) (“SkinBioTherapeutics” or the “Company”), a life sciences company focused on skin health, announces that it has raised a total of £1,500,000 via a placing of 9,375,000 new ordinary shares (“Placing Shares”) at a price of 16 pence per share (the “Placing”).

Read more »

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) from sophisticated and institutional investors that will result in 12,857,143 fully paid ordinary shares being issued at AUD$0.14 per share (Placement).

Read more »

Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art research and development (R&D) facility at Milton Park, Oxfordshire.

Read more »

HOOKIPA Appoints Michael A. Kelly as Independent Director

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors.

Read more »